{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pharm:pharm-006-reversal-agents",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": ["copilot-agent", "knowledge-graph-agent"],
    "confidence": 0.95,
    "status": "validated",
    "copyright_compliance": "Original content based on general medical knowledge"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pharmacology",
    "type": "pharmacology",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "PHARM-006",
    "keywords": ["reversal agents", "protamine", "vitamin K", "idarucizumab", "andexanet", "PCC"],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "anticoagulation_reversal",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Anticoagulant Reversal Agents",
    "statement": {
      "text": "Anticoagulant reversal agents provide specific or non-specific antagonism of anticoagulation for emergent surgery or life-threatening bleeding, with agent selection based on the anticoagulant being reversed.",
      "formal": "Heparin: Protamine; Warfarin: Vitamin K + PCC/FFP; Dabigatran: Idarucizumab; Factor Xa inhibitors: Andexanet alfa or 4F-PCC"
    },
    "explanation": {
      "intuition": "When a patient on blood thinners needs urgent surgery or is bleeding badly, we need antidotes to rapidly turn off the anticoagulation. Each blood thinner has its own specific reversal strategy.",
      "key_insight": "Know your reversal agents - emergent surgery on anticoagulated patients requires rapid decision-making about which reversal strategy to use.",
      "technical_details": "Anticoagulant reversal strategies range from specific antidotes (protamine for heparin, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) to non-specific procoagulant replacement (prothrombin complex concentrates, fresh frozen plasma). Warfarin reversal combines vitamin K (slow, complete reversal) with PCC or FFP (rapid, temporary). Direct oral anticoagulants (DOACs) have varying reversal options - dabigatran has specific reversal (idarucizumab), while factor Xa inhibitors can use andexanet alfa or PCC off-label.",
      "common_misconceptions": [
        "All anticoagulants can be reversed with vitamin K - FALSE, only warfarin",
        "FFP completely reverses warfarin quickly - FALSE, limited effect, volume-dependent",
        "DOACs cannot be reversed - FALSE, specific reversal agents now available",
        "Protamine reverses all heparin-based drugs equally - FALSE, less effective for LMWH"
      ]
    },
    "reversal_by_agent": {
      "heparin_ufh": {
        "reversal_agent": "Protamine sulfate",
        "dose": "1 mg per 100 units heparin",
        "considerations": [
          "Give slowly (over 10 min) to avoid hypotension",
          "Half-life considerations",
          "Caution: Fish allergy, NPH insulin exposure"
        ],
        "effectiveness": "Complete reversal"
      },
      "lmwh": {
        "reversal_agent": "Protamine sulfate",
        "dose": "1 mg per 1 mg enoxaparin (if <8 hours)",
        "considerations": [
          "Only 60% reversal of anti-Xa activity",
          "May need repeat dose"
        ],
        "effectiveness": "Partial reversal"
      },
      "warfarin": {
        "acute_reversal": {
          "agents": ["4-factor PCC (Kcentra)", "3-factor PCC", "FFP"],
          "pcc_dose": "25-50 units/kg based on INR",
          "effectiveness": "Rapid (15-30 min with PCC)"
        },
        "sustained_reversal": {
          "agent": "Vitamin K (phytonadione)",
          "dose": "5-10 mg IV",
          "onset": "6-24 hours",
          "duration": "Complete, sustained reversal"
        },
        "strategy": "PCC + vitamin K for major bleeding"
      },
      "dabigatran": {
        "specific_reversal": {
          "agent": "Idarucizumab (Praxbind)",
          "dose": "5 g IV (two 2.5 g vials)",
          "mechanism": "Monoclonal antibody fragment binding dabigatran",
          "effectiveness": "Complete, immediate reversal"
        },
        "alternative": "Hemodialysis (dabigatran is dialyzable)"
      },
      "factor_xa_inhibitors": {
        "specific_reversal": {
          "agent": "Andexanet alfa (Andexxa)",
          "dose": "Based on drug and timing of last dose",
          "mechanism": "Decoy factor Xa that binds inhibitor",
          "cost": "Very expensive"
        },
        "non_specific": {
          "agent": "4-factor PCC (off-label)",
          "dose": "25-50 units/kg",
          "evidence": "Limited but used commonly"
        }
      }
    },
    "pcc_details": {
      "four_factor_pcc": {
        "contents": "Factors II, VII, IX, X + Protein C, S",
        "indications": ["Warfarin reversal", "DOAC reversal (off-label)"],
        "dosing_by_inr": {
          "inr_2_4": "25 units/kg",
          "inr_4_6": "35 units/kg",
          "inr_greater_6": "50 units/kg"
        }
      },
      "vs_ffp": {
        "advantages_pcc": ["Faster", "Lower volume", "More effective"],
        "when_ffp": "If PCC unavailable, massive transfusion"
      }
    },
    "clinical_scenarios": {
      "emergent_surgery": [
        "Assess time since last anticoagulant dose",
        "Choose appropriate reversal based on agent",
        "Monitor for adequacy of reversal"
      ],
      "life_threatening_bleeding": [
        "Immediate reversal regardless of surgery",
        "Resuscitation concurrent with reversal",
        "Consider tranexamic acid as adjunct"
      ]
    },
    "terminology": {
      "snomed_ct": "410942007",
      "icd_10": "T45.515A"
    }
  },
  "skos": {
    "prefLabel": {"@language": "en", "@value": "Anticoagulant Reversal Agents"},
    "altLabel": ["Antidotes to Anticoagulation", "Reversal Strategies", "Praxbind", "Andexxa"],
    "definition": {"@language": "en", "@value": "Pharmacologic agents used to reverse the effects of anticoagulants for emergent surgery or life-threatening bleeding."},
    "notation": "PHARM-006"
  },
  "clinical_features": {
    "presentation": [
      "Anticoagulated patient requiring emergent surgery",
      "Life-threatening bleeding on anticoagulation",
      "Supratherapeutic INR with bleeding"
    ],
    "diagnosis": [
      "Identify which anticoagulant patient is taking",
      "Check INR, PTT, or drug levels if available",
      "Assess severity of bleeding"
    ],
    "treatment": [
      "Select appropriate reversal agent",
      "Administer reversal with monitoring",
      "Confirm adequacy of reversal before surgery"
    ]
  },
  "relationships": {
    "prerequisites": ["vascular:pharm:pharm-001-heparin", "vascular:pharm:pharm-005-warfarin"],
    "enables": ["vascular:procedures:emergent-surgery", "vascular:complications:bleeding-management"],
    "skos:broader": ["vascular:pharm:anticoagulation"],
    "skos:related": ["vascular:complications:bleeding", "vascular:procedures:massive-transfusion"],
    "skos:narrower": []
  },
  "provenance": {
    "sources": [
      {
        "type": "clinical_guideline",
        "reference": "ACCP Guidelines on Anticoagulation Reversal",
        "evidence_level": "B"
      },
      {
        "type": "clinical_guideline",
        "reference": "AHA/ASA Guidelines on Reversal",
        "evidence_level": "B"
      }
    ]
  },
  "pedagogical": {
    "target_audience": ["vascular surgery residents", "emergency medicine residents", "anesthesiology residents"],
    "estimated_time": "20min",
    "learning_objectives": [
      "Match anticoagulants with their specific reversal agents",
      "Calculate appropriate PCC dosing for warfarin reversal",
      "Apply reversal strategies in emergent surgical scenarios",
      "Compare specific vs non-specific reversal options for DOACs"
    ],
    "clinical_pearls": [
      "Heparin → Protamine (1:100 ratio); Warfarin → PCC + Vitamin K",
      "Dabigatran → Idarucizumab (5g); Factor Xa inhibitors → Andexanet or PCC",
      "PCC works faster than FFP and with less volume",
      "Always give vitamin K with PCC for sustained warfarin reversal",
      "Dabigatran is dialyzable - consider if idarucizumab unavailable"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "410942007",
      "codingSystem": "SNOMED-CT",
      "name": "Anticoagulant reversal"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "T45.515A",
      "codingSystem": "ICD-10-CM",
      "name": "Adverse effect of anticoagulants"
    }
  ]
}
